Ensifentrine is a small molecule commercialized by Verona Pharma, with a leading Pre-Registration program in Chronic Obstructive Pulmonary Disease (COPD). According to Globaldata, it is involved in 32 clinical trials, of which 26 were completed, 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Ensifentrine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Ensifentrine is expected to reach an annual total of $1.99 bn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Ensifentrine Overview

Ensifentrine (RPL-554) is under development for the treatment of allergic asthma, mild to moderate chronic asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, cystic fibrosis, non cystic fibrosis bronchiectasis and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered through inhalation route as a suspension. RPL-554 acts by targeting both phosphodiesterase 3 and phosphodiesterase 4 enzymes. It was also under development for the treatment of allergic rhinitis.

Verona Pharma Overview

Verona Pharma is a clinical-stage biopharmaceutical company that focuses on the development and marketing of therapies for the treatment of respiratory diseases. The company’s lead investigating candidate, ensifentrine, a bronchodilator/anti-inflammatory agent intended for the treatment of chronic obstructive pulmonary disease (COPD) in Phase III clinical trials. Additionally the company is evaluating ensifentrine for the treatment of cystic fibrosis and asthma under its Phase II trials. Verona Pharma is headquartered in London, the UK.
The company reported revenues of (US Dollars) US$0.5 million for the fiscal year ended December 2022 (FY2022), a decrease of 98.9% over FY2021. The operating loss of the company was US$76.6 million in FY2022, compared to an operating loss of US$73.3 million in FY2021. The net loss of the company was US$68.7 million in FY2022, compared to a net loss of US$55.6 million in FY2021.

For a complete picture of Ensifentrine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.